Trials Support NfL Levels as Marker of Disease Activity in Relapsing MS

Trials Support NfL Levels as Marker of Disease Activity in Relapsing MS

301557

Trials Support NfL Levels as Marker of Disease Activity in Relapsing MS

Larger declines with treatment in blood levels of neurofilament light chain (NfL), a marker of nerve cell damage, are associated with fewer brain lesions, less brain shrinkage, and lower relapse rates in people with relapsing forms of multiple sclerosis (MS), a study reported. These results, based on a post-hoc analysis of two Phase 3 clinical trials that supported the approval of Zeposia (ozanimod) to treat relapsing MS, add to previous studies linking high NfL levels with greater…

You must be logged in to read/download the full post.